Valuation of Edgewise Therapeutics, Inc. (EWTX): TTM P/E 4.75, P/B 2.59, EV/EBITDA 3.5, dividend yield 0.00%. The price range it would trade at on its usual multiples and on its sector's, with its peers' multiples and a comparison against other Healthcare companies.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $38.87 (closing price, November 5, 2026), EWTX trades at a P/E of 4.75 and an ROE of 130.43%. Market capitalisation stands at $4.2B.
Balance sheet quality for EWTX: debt-to-equity ratio of 0.00, current ratio of 12.30 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 4.75 |
| Price / Book | 2.59 |
| EV / EBITDA | 3.5 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| EWTX | Edgewise Therapeutics, Inc. | $4.2B | 4.75 | 2.59 | 130.4% |
| PTCT | PTC Therapeutics, Inc. | $5.5B | 57.1% | ||
| DYN | Dyne Therapeutics, Inc. | $3.2B | 3.39 | -69.7% | |
| VRTX | Vertex Pharmaceuticals Incorporated | $137.5B | 34.91 | 6.58 | 20.1% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| MRNA | Moderna, Inc. | $96.4B | 14.14 | -39.2% | |
| REGN | Regeneron Pharmaceuticals, Inc. | $93.4B | 19.95 | 2.87 | 15.1% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
Price
| Price | $38.87 (closing price, November 5, 2026) |
| Market Cap | $4.2B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 130.43% |
| Return on Invested Capital | -11.55% |
| Return on Assets | 56.72% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: PTCT · DYN · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of EWTX: Overview · Financials · Estimates · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks